AU2002222139A1 - Hcv vaccines - Google Patents

Hcv vaccines

Info

Publication number
AU2002222139A1
AU2002222139A1 AU2002222139A AU2213902A AU2002222139A1 AU 2002222139 A1 AU2002222139 A1 AU 2002222139A1 AU 2002222139 A AU2002222139 A AU 2002222139A AU 2213902 A AU2213902 A AU 2213902A AU 2002222139 A1 AU2002222139 A1 AU 2002222139A1
Authority
AU
Australia
Prior art keywords
hcv vaccines
hcv
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002222139A
Other languages
English (en)
Inventor
Jean-Pierre Allain
Chengyao Li
Enza Piccolella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge University Technical Services Ltd CUTS
Universita degli Studi di Roma La Sapienza
Original Assignee
Cambridge University Technical Services Ltd CUTS
Universita degli Studi di Roma La Sapienza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0030102A external-priority patent/GB0030102D0/en
Priority claimed from GB0030789A external-priority patent/GB0030789D0/en
Application filed by Cambridge University Technical Services Ltd CUTS, Universita degli Studi di Roma La Sapienza filed Critical Cambridge University Technical Services Ltd CUTS
Publication of AU2002222139A1 publication Critical patent/AU2002222139A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2002222139A 2000-12-09 2001-12-07 Hcv vaccines Abandoned AU2002222139A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0030102.8 2000-12-09
GB0030102A GB0030102D0 (en) 2000-12-09 2000-12-09 HCV vaccines
GB0030789A GB0030789D0 (en) 2000-12-18 2000-12-18 HCV vaccines
GB0030789.2 2000-12-18
PCT/GB2001/005421 WO2002045743A2 (fr) 2000-12-09 2001-12-07 Vaccins contre le virus de l'hepatite c

Publications (1)

Publication Number Publication Date
AU2002222139A1 true AU2002222139A1 (en) 2002-06-18

Family

ID=26245410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002222139A Abandoned AU2002222139A1 (en) 2000-12-09 2001-12-07 Hcv vaccines

Country Status (2)

Country Link
AU (1) AU2002222139A1 (fr)
WO (1) WO2002045743A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041432A2 (fr) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Neutralisation croisee du vhc avec des proteines recombinantes
SG10201701181XA (en) * 2012-08-16 2017-04-27 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
EP4430061A1 (fr) * 2021-11-11 2024-09-18 University Health Network Vaccins polyvalents et leurs procédés de fabrication

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810756D0 (en) * 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof

Also Published As

Publication number Publication date
WO2002045743A3 (fr) 2004-01-08
WO2002045743A2 (fr) 2002-06-13

Similar Documents

Publication Publication Date Title
GB0020953D0 (en) Vaccine
HUP0301092A3 (en) Vaccine
IL155072A0 (en) Vaccine
HUP0402067A3 (en) Vaccines
AU1591402A (en) Vaccine
AU1813901A (en) Chimeric flavivirus vaccines
GB0024200D0 (en) Component vaccine
GB0014288D0 (en) Vaccine
AU5977700A (en) Vaccines
AU2001240791A1 (en) Sequence
AU2002222139A1 (en) Hcv vaccines
GB0014845D0 (en) Vaccine
GB0026334D0 (en) Vaccine
AU2001267541A1 (en) Vaccine composition
GB0025694D0 (en) Vaccine
GB0003082D0 (en) Vaccine
GB0004533D0 (en) Vaccines
GB0015722D0 (en) Vaccine
GB0006693D0 (en) Vaccine
AU2001266534A1 (en) Papillomavirus vaccine
GB0027433D0 (en) Vaccine component
GB0030102D0 (en) HCV vaccines
GB0030789D0 (en) HCV vaccines
AU2001285773A1 (en) Vaccine
GB0015935D0 (en) Vaccine